- AU$33.90m
- -AU$33.93m
- AU$14.60m
Australia's Immutep slumps on completing discounted equity raising
Brief: Immutep Announces A$80 Mln Fully Underwritten Equity Raising
Brief: Immutep Seeks Trading Halt
Immutep rises as combination therapy shows results in lung cancer trial
Brief: Immutep Announces Promising New Clinical Data From Triple Combination Therapy In Insight-003 Trial
Aussie Immutep at near 1-year high on positive data from cancer therapy study
Immutep surges on positive data from cancer therapy study
Australia's Immutep jumps most in a year on Phase 2 trial results
Australia's Immutep rises on positive US FDA feedback for lung cancer drug
Brief: Immutep Receives Approval To Initiate Insight-005 Trial Evaluating Eftilagimod Alpha And Anti-Pd-L1 Therapy Bavencio
Brief: Immutep Appoints Florian Vogl As Chief Medical Officer
Brief: Immutep Announces Initiation Of Investigator-Initiated Phase Ii Trial In Soft Tissue Sarcoma In Neoadjuvant Setting
Australia's Immutep drops as Lucy Turnbull quits board
Brief: Immutep Announces Positive Final Data In 2nd Line Metastatic Nsclc Patients Refractory To Anti-Pd-(L)1 Therapy At European Lung Cancer Congress 2023
Immutep rises on plans to expand cancer drug trial
Brief: Immutep Announces Expansion Of Triple Combination Therapy
Brief: Immutep Announces Initiation Of Phase II/III Trial For Eftilagimod Alpha Plus Paclitaxel
Brief: Immutep Says HY Total Revenue And Other Income A$2.6 Mln
Brief: Immutep Reaches Enrolment Target For INSIGHT-003 Trial In 1st Line NSCLC